G
Gisèle Lacoste
Researcher at Transgene SA
Publications - 13
Citations - 523
Gisèle Lacoste is an academic researcher from Transgene SA. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 7, co-authored 11 publications receiving 471 citations.
Papers
More filters
Journal ArticleDOI
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
Elisabeth Quoix,Rodryg Ramlau,Virginie Westeel,Z. Papai,A. Madroszyk,Alain Rivière,Piotr Koralewski,Jean-Luc Breton,Erich Stoelben,Denis Braun,Didier Debieuvre,Hervé Lena,Marc Buyse,Marie-Pierre Chenard,Bruce Acres,Gisèle Lacoste,Bérangère Bastien,Annette Tavernaro,Nadine Bizouarne,Jean-Yves Bonnefoy,Jean-Marc Limacher +20 more
TL;DR: This phase 2B study suggests that TG4010 enhances the effect of chemotherapy in advanced NSCLC, with a target rate of 40% or higher in the experimental group.
Journal ArticleDOI
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Elisabeth Quoix,Hervé Lena,György Losonczy,Frederic Forget,Christos Chouaid,Z. Papai,Radj Gervais,Christian H. Ottensmeier,Aleksandra Szczesna,Andrzej Kazarnowicz,J.T. Beck,Virginie Westeel,Enriqueta Felip,Didier Debieuvre,A. Madroszyk,Julien Adam,Gisèle Lacoste,Annette Tavernaro,Bérangère Bastien,Céline Halluard,Tania Palanché,Jean Marc Limacher +21 more
TL;DR: The primary endpoint was progression-free survival, assessed every 6 weeks, to validate the predictive value of the TrPAL biomarker, and patients with TrPal values of greater than the ULN had a Bayesian probability of more than 95% that the true hazard ratio (HR) for progression- free survival was less than 1.
Journal ArticleDOI
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma
Reinhard Dummer,Christoph Rochlitz,Thierry Velu,Bruce Acres,Jean-Marc Limacher,Pascal Bleuzen,Gisèle Lacoste,Philippe Slos,Pedro Romero,Mirjana Urosevic +9 more
TL;DR: Evaluated intratumoral injections of adenovirus-IL-2 (TG1024) in patients with advanced solid tumors and melanoma show that they are safe and well tolerated and the clinical activity observed in this study warrants further investigations.
Journal ArticleDOI
Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Rodryg Ramlau,Virginie Westeel,Z. Papai,A. Riviere,A. Madroszyk,P. Koralewski,Gisèle Lacoste,Bruce Acres,Jean-Marc Limacher,E. Quoix +9 more
TL;DR: Primary endpoint was progression-free survival at 6 months; secondary endpoints included overall survival, response rate, safety, quality of life and immune response.
Journal ArticleDOI
Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial.
Christine Rotonda,Amélie Anota,Mariette Mercier,Bérangère Bastien,Gisèle Lacoste,Jean-Marc Limacher,Elisabeth Quoix,Franck Bonnetain +7 more
TL;DR: Adding therapeutic vaccination with TG4010 to standard chemotherapy in patients with advanced NSCLC is associated with a similar evolution in HRQOL compared to chemotherapy alone, and the smokers and the former smokers seemed to present a shorter TUDD of FWB domain.